# Cerebrum (cerebrum) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cerebrum

> The PDUFA target action date for Cerebrum (cerebrum), sponsored by Praxis Precision Medicines, Inc. (PRAX), is January 29, 2027, for essential tremor, or ET. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Cerebrum (cerebrum) PDUFA date?

The PDUFA target action date for Cerebrum (cerebrum), sponsored by Praxis Precision Medicines, Inc. (PRAX), is January 29, 2027, for essential tremor, or ET. Status: scheduled. SEC Form 10-Q: "For our ulixacaltamide program within the Cerebrum™ platform, we submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor, or ET, to the FDA based on the positive results of our two studies in the Phase 3 Essential3 program in ET, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/cerebrum)

Source: SEC Form 10-Q, accession 0001689548-26-000089, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/cerebrum#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cerebrum (cerebrum) |
| Codes |  |
| Sponsor | Praxis Precision Medicines, Inc. (PRAX) https://sec-api.dev/companies/prax/catalysts |
| Indications | essential tremor, or et |
| Modality |  |
| FDA designations | breakthrough |

## Timeline

### Oct 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-02-19, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001689548-26-000047): "For our ulixacaltamide program within the Cerebrum™ platform, we announced positive topline results for the two studies in the Phase 3 Essential3 program in essential tremor, or ET, in October 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- SEC Form 10-K (accession 0001689548-26-000029): "For our ulixacaltamide program within the Cerebrum™ platform, we announced positive topline results for the two studies in the Phase 3 Essential3 program in essential tremor, or ET, in October 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm

### January 29, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3. Indication: essential tremor, or ET.
- First seen 2026-04-14, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001689548-26-000089): "For our ulixacaltamide program within the Cerebrum™ platform, we submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor, or ET, to the FDA based on the positive results of our two studies in the Phase 3 Essential3 program in ET, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "For our ulixacaltamide program within the Cerebrum™ platform, we submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor, or ET, to the FDA based on the positive results of our two studies in the Phase 3 Essential3 program in ET, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000086): "•The New Drug Application (NDA) for ulixacaltamide remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "•NDA review is progressing as expected, with a PDUFA date of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "•The FDA has accepted Praxis' NDA for ulixacaltamide for the treatment of ET and has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- SEC Form 8-K (accession 0001689548-26-000033): "The FDA has set a target action date under the Prescription Drug User Fee Act of January 29, 2027 and is not planning to hold an advisory committee meeting." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000033/prax-20260414.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "We submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of ET to the FDA, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000091): "19 E S S E N T I A L T R E M O R Ulixacaltamide The first medicine designed for essential tremor Jan 29, 2027 PDUFA date" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cerebrum.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cerebrum (cerebrum) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cerebrum

```bibtex
@misc{secapidev_pdufa_cerebrum_20261116,
  title        = {Cerebrum (cerebrum) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cerebrum}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cerebrum_20261116","title":"Cerebrum (cerebrum) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cerebrum","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
